{"filing":{"accession_number":"0001193125-26-257368","cik":"0001422143","ticker":"KURA","company_name":"Kura Oncology, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"kura-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/kura-20260604.htm"},"events":[{"id":6796,"run_id":5955,"accession_number":"0001193125-26-257368","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Kura Oncology held its Annual Meeting of Stockholders on June 4, 2026, with shareholders voting on six proposals including director elections, auditor ratification, Say-on-Pay advisory vote, Say-on-Pay frequency, and approval of amendments to the 2014 Equity Incentive Plan and ESPP.","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4321,"accession_number":"0001193125-26-257368","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on Board and stockholder approval of amendments to the 2014 Equity Incentive Plan and ESPP, increasing authorized shares by 6.5 million and 2.5 million respectively. This is a compensatory arrangement amendment affecting equity grant capacity and is material to investors assessing dilution and executive compensation policy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:46.793463+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4322,"accession_number":"0001193125-26-257368","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Kura Oncology's June 4, 2026 Annual Meeting of Stockholders, including detailed vote tallies for six proposals: director elections, auditor ratification, Say-on-Pay advisory vote, frequency of Say-on-Pay votes, approval of Amended 2014 Plan, and approval of Amended ESPP. The filing directly matches Item 5.07 requirements and is material as it documents stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:46.793463+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4321,"accession_number":"0001193125-26-257368","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on Board and stockholder approval of amendments to the 2014 Equity Incentive Plan and ESPP, increasing authorized shares by 6.5 million and 2.5 million respectively. This is a compensatory arrangement amendment affecting equity grant capacity and is material to investors assessing dilution and executive compensation policy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:46.793463+00:00","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-06-04"},{"id":4322,"accession_number":"0001193125-26-257368","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Kura Oncology's June 4, 2026 Annual Meeting of Stockholders, including detailed vote tallies for six proposals: director elections, auditor ratification, Say-on-Pay advisory vote, frequency of Say-on-Pay votes, approval of Amended 2014 Plan, and approval of Amended ESPP. The filing directly matches Item 5.07 requirements and is material as it documents stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:46.793463+00:00","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-06-04"}]}